|
Website:
http://www.novartis.com
Phone: +41 61 324 1111 |
Address:
CH-4002 Basel
4002 Basel, |
Company Description
Novartis AG. The Group's principal activity is the development and manufacture of pharmaceuticals and nutritional products. The Group operates through four divisions; Pharmaceuticals, Consumer Health, Sandoz & Vaccines & Diagnostics. Pharmaceuticals Division includes drugs for use in transplantations, central nervous system disorders, cardiovascular, endocrine and respiratory diseases, dermatology, oncology, hematology and rheumatism and bone and hormone replacement therapy. Consumer Health Division includes Generics/OTC and sells copies of prescription medicines no longer under patent protection; medical nutrition and self-medication. Sandoz Division: Manufactures, distributes and sells generic pharmaceutical products and substances no longer subject to patent protection. Vaccines & Diagnostics Division provides innovative vaccines and a range of conventional products to combat viral and bacterial diseases. In 2006, the Group acquired Chiron Corporation & NeuTec Pharma plc. Pharmaceuticals accounted for 63% of 2006 revenues, Consumer Health, 18%, Sandoz, 17% & Vaccines & Diagnostics, 2%
Key People
| Chairman, President & Chief Executive | Dr. Daniel Vasella |
| Chief Financial Officer | Raymund Breu |
| Vice Chairman | Prof. Ulrich Lehner |
| Vice Chairman | Hans-Joerg Rudloff |
| Secretary | Monika Matti |
Related Business Topics
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
N
Novartis AG
Discovers, develops, manufactures and markets arthritis, inflammation, bone, cardiovascular, metabolic, dermatology, hematology, neuroscience, and oncology drugs.
www.novartis.com
Discovers, develops, manufactures and markets arthritis, inflammation, bone, cardiovascular, metabolic, dermatology, hematology, neuroscience, and oncology drugs.
www.novartis.com
Breaking News
SINA - 17 hours ago
(Beijing Time) Xinhua English GENEVA, Nov. 13 (Xinhua) -- The Swiss authorities on Friday authorized a new vaccine against the A/H1N1 influenza which is made using cell cultures instead of the traditional egg-based methods. The vaccine, named Celtura, ...
Reuters - November 13, 2009 9:32 AM
* Celtura third Swine flu vaccine approved in Switzerland * Cleared for use in adults, children from 3 years * Those over 40 need two doses ZURICH, Nov 13 (Reuters) - Switzerland has approved Swiss drugmaker Novartis AG's (NOVN.VX) Celtura H1N1 swine flu ...
Forbes.com - November 13, 2009 8:56 AM
ZURICH, Nov 13 (Reuters) - Switzerland has approved Swiss drugmaker Novartis AG's Celtura H1N1 swine flu vaccine as it rolls out its national vaccination programme ahead of the winter flu season, regulators said on Friday. Swissmedic said it was adding ...
Reuters UK - November 13, 2009 8:41 AM
* Celtura third Swine flu vaccine approved in Switzerland * Cleared for use in adults, children from 3 years * Those over 40 need two doses ZURICH, Nov 13 (Reuters) - Switzerland has approved Swiss drugmaker Novartis AG's (NOVN.VX) Celtura H1N1 swine flu ...
ABC News - November 13, 2009 7:06 AM
Serbia's health authorities have ordered three million swine flu vaccines from Swiss pharmaceutical company Novartis AG worth an estimated euro24 million ($36 million). Health officials said Friday the first shipment of some 500,000 doses is to arrive ...
Pfizer and Wyeth
Pfizer & Wyeth Are Joining Together to Work for a Healthier World.
www.Pfizer.com/Pfizer&Wyeth
Pfizer & Wyeth Are Joining Together to Work for a Healthier World.
www.Pfizer.com/Pfizer&Wyeth
